Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ThermoGenesis Holdings, Inc. (THMO)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Medical - Devices
Address
2711 Citrus Road 95742
Rancho Cordova, CA, US
Rancho Cordova, CA, US
CEO
Xiaochun Xu
Website
thermogenesis.com
IPO
1987-06-05
CIK 811212 ISIN US88362L2097
Description
ThermoGenesis Holdings, Inc., founded in 1986 and based in Rancho Cordova, California, is a global innovator specializing in automated systems for cell-banking, cell-processing, and cell-based therapeutic applications. The company's advanced solutions are available across the United States, China, the United Arab Emirates, Vietnam, and other international regions. Its product portfolio encompasses medical devices crucial for automated cell processing. For clinical bio-banking purposes, ThermoGenesis provides the AXP II Automated Cell Separation System, a fully closed system designed for isolating stem and progenitor cells from umbilical cord blood. Complementing this is the BioArchive Automated Cryopreservation System, a robotic, liquid nitrogen-controlled system for both freezing and long-term cryogenic storage of cord blood samples and cell therapeutic products used in clinical environments. In the realm of point-of-care applications, the company offers the XP Point-of-Care System, an automated, sterile, and closed platform that facilitates the rapid processing of autologous stem cells derived from peripheral blood or bone marrow aspirate directly within clinical settings such as surgical centers. Additionally, the PXP-1000 System is another automated, closed solution, engineered for fast and reproducible separation of multiple cellular components from blood with minimal red blood cell contamination. For general laboratory use, ThermoGenesis provides its X-Series cell processing products, including X-Lab for cell isolation, the X-Wash System for efficient cell washing and reformulation, and X-Mini for high-efficiency, small-scale cell purification. Beyond its product offerings, the company also delivers contract development and manufacturing (CDMO) services specifically for cell and cell-based gene therapies. Its medical device products are marketed and sold through a network of independent distributors, as well as directly to end-user customers. The company, formerly known as Cesca Therapeutics Inc., officially adopted the name ThermoGenesis Holdings, Inc. in November 2019.
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Date | Filing |
|---|---|---|
| TotipotentRX | 2013-11-08 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
313
Beta
8.03
Float Shares
3.51M
Free Float %
22.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -99.99% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Buy
Price Targets & DCF
Current price
0.00
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-41.88
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%-9.9% Q1'24: +6.4% (vs Q1'23)
-
EPS growth Medical - Devices: +28.5%+62.9% ★ Q1'24: +88.7% (vs Q1'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%-179.3% Q1'24: -19.2% (vs Q1'23)
-
EBIT margin Medical - Devices: +6.2%-94.1% Q1'24: -20.1% (vs Q1'23)
-
ROIC Medical - Devices: +3.3%-178.7% Q1'24: -47.1% (vs Q1'23)
-
Share dilution Medical - Devices: 0.0%+329.8% Q1'24: +222.2% (vs Q1'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-1.36× Q1'24: -8.05× (vs Q1'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
16.04M
est: 16.83M (-4.7%)
|
11.93M
est: 11.95M (-0.2%)
|
14.53M
est: 12.17M (+19.4%)
|
12.03M
est: 12.17M (-1.2%)
|
9.67M
est: 9.75M (-0.8%)
|
13.05M
est: 18.42M (-29.2%)
|
9.74M
est: 10.40M (-6.3%)
|
9.29M
est: 10.30M (-9.8%)
|
10.48M
est: 11.40M (-8.0%)
|
9.45M
est: 11.40M (-17.1%)
|
16.90M
est.
|
21.11M
est.
|
24.61M
24.61M – 24.61M
+16.6% YoY
|
25.12M
25.12M – 25.12M
+2.1% YoY
|
| EBITDA |
-13.49M
est: -10.37M (-30.0%)
|
-9.70M
est: -7.37M (-31.6%)
|
-8.42M
est: -7.50M (-12.2%)
|
-8.55M
est: -7.50M (-14.0%)
|
-42.30M
est: -6.01M (-603.8%)
|
-4.81M
est: -11.35M (+57.6%)
|
-8.16M
est: -6.41M (-27.3%)
|
-5.14M
est: -3.39M (-51.6%)
|
-5.27M
est: -4.15M (-26.9%)
|
-7.74M
est: -5.13M (-50.9%)
|
-10.42M
est.
|
-13.01M
est.
|
-15.17M
-15.17M – -15.17M
-16.6% YoY
|
-15.48M
-15.48M – -15.48M
-2.1% YoY
|
| EBIT |
-14.84M
est: -11.78M (-26.0%)
|
-10.60M
est: -8.36M (-26.7%)
|
-9.25M
est: -8.52M (-8.6%)
|
-9.20M
est: -8.52M (-8.0%)
|
-42.97M
est: -6.82M (-529.8%)
|
-5.62M
est: -12.89M (+56.4%)
|
-8.90M
est: -7.28M (-22.3%)
|
-5.78M
est: -6.59M (+12.3%)
|
-6.20M
est: -7.45M (+16.8%)
|
-8.89M
est: -8.91M (+0.3%)
|
-11.83M
est.
|
-14.77M
est.
|
-17.22M
-17.22M – -17.22M
-16.6% YoY
|
-17.58M
-17.58M – -17.58M
-2.1% YoY
|
| Net Income |
-14.85M
est: -8.84B (+99.8%)
|
-18.59M
est: -5.19B (+99.6%)
|
-29.10M
est: -4.82B (+99.4%)
|
-4.57M
est: -4.82B (+99.9%)
|
-39.72M
est: -2.04B (+98.0%)
|
-9.50M
est: -47.95M (+80.2%)
|
-16.35M
est: -268.54M (+93.9%)
|
-11.38M
est: -6.96M (-63.5%)
|
-11.27M
est: -8.39M (-34.3%)
|
-17.98M
est: -10.28M (-74.8%)
|
189.4K
est.
|
473.6K
est.
|
734.1K
734.1K – 734.1K
+55.0% YoY
|
828.8K
828.8K – 828.8K
+12.9% YoY
|
| SGA |
13.67M
est: 12.71M (+7.6%)
|
10.38M
est: 9.02M (+15.0%)
|
12.40M
est: 9.19M (+35.0%)
|
9.61M
est: 9.19M (+4.6%)
|
9.65M
est: 7.36M (+31.0%)
|
8.03M
est: 13.91M (-42.2%)
|
7.68M
est: 7.85M (-2.2%)
|
8.52M
est: 7.84M (+8.6%)
|
7.24M
est: 8.83M (-18.0%)
|
7.22M
est: 10.56M (-31.6%)
|
12.76M
est.
|
15.94M
est.
|
18.58M
18.58M – 18.58M
+16.6% YoY
|
18.97M
18.97M – 18.97M
+2.1% YoY
|
| EPS |
-3,312.96
est: -3,735.00 (+11.3%)
|
-2,778.48
est: -2,191.50 (-26.8%)
|
-1,320.40
est: -2,034.00 (+35.1%)
|
-203.28
est: -2,034.00 (+90.0%)
|
-971.34
est: -859.50 (-13.0%)
|
-151.09
est: -20.25 (-646.1%)
|
-117.20
est: -113.40 (-3.4%)
|
-43.41
est: -36.00 (-20.6%)
|
-20.45
est: -14.40 (-42.0%)
|
-7.59
est: -4.35 (-74.5%)
|
0.08
est.
|
0.20
est.
|
0.31
0.31 – 0.31
+55.0% YoY
|
0.35
0.35 – 0.35
+12.9% YoY
|
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-4.84M
OE per share TTM
-1.58
Owner's Yield
-1,202,564.71%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
31.8%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
25
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Xiaochun Xu | 71.12M | 67.84% | 133.3K | 70.98M | 133.3K | 10.00 | IN | China | 2022-11-09 | ↗ |
| 2 | Boyalife Group Inc. | 70.98M | 67.71% | — | 70.98M | — | 10.00 | CO | Illinois corporation | 2022-11-09 | ↗ |
| 3 | Boyalife (Hong Kong) Limited | 10.37M | 69.10% | — | 10.37M | — | 10.00 | CO | China | 2018-04-27 | ↗ |
| 4 | Yishu Li | 10.37M | 69.10% | — | 10.37M | — | 10.00 | IN | China | 2018-04-27 | ↗ |
| 5 | FMR Corp. | 5.95M | 10.84% | 61.8K | — | 5.95M | — | HC | Delaware | 2006-11-13 | ↗ |
| 6 | Mitchel Sivilotti | 4.62M | 14.16% | 4.62M | — | 4.62M | — | IN | United States | 2014-02-28 | ↗ |
| 7 | Jon D. Gruber | 4.57M | 8.20% | 882.0K | 3.69M | 882.0K | 3.69M | IN | United States | 2010-01-29 | ↗ |
| 8 | Kenneth L. Harris | 4.55M | 13.94% | 4.55M | — | 4.55M | — | IN | United States | 2014-02-28 | ↗ |
| 9 | Winslow Management Company, LLC | 4.51M | 8.05% | 4.51M | — | 4.51M | — | IA | U.S., Delaware | 2009-02-17 | ↗ |
| 10 | Edward C. Johnson 3d | 4.35M | 7.77% | — | — | 4.35M | — | IN | United States of America | 2008-12-10 | ↗ |
| 11 | Boyalife Asset Holding II, Inc. | 1.98M | 14.70% | — | 1.98M | — | 10.00 | CO | Illinois corporation | 2018-04-27 | ↗ |
| 12 | Daniel B. Asher | 100.3K | 1.80% | — | 100.3K | — | 100.3K | HC, IN | United States of America | 2020-04-03 | ↗ |
| 13 | Intracoastal Capital LLC | 100.3K | 1.80% | — | 100.3K | — | 100.3K | OO | United States of America | 2020-04-03 | ↗ |
| 14 | Mitchell P. Kopin | 100.3K | 1.80% | — | 100.3K | — | 100.3K | HC, IN | United States of America | 2020-04-03 | ↗ |
| 15 | State of New Jersey Common Pension Fund B | 69.5K | 13.80% | — | 240.4K | — | 240.4K | EP | California | 2012-02-17 | ↗ |
| 16 | 13-3127734 | — | 0.00% | — | — | — | — | HC | Delaware | 2021-02-11 | ↗ |
| 17 | 26-0385758 | — | 0.00% | — | — | — | — | IA | Delaware | 2021-02-11 | ↗ |
| 18 | Armistice Capital Master Fund Ltd. | — | 0.00% | — | — | — | — | CO | Delaware | 2020-04-06 | ↗ |
| 19 | Armistice Capital, LLC | — | 0.00% | — | — | — | — | IA, OO | Delaware | 2020-04-06 | ↗ |
| 20 | Boyalife Investment Inc. | — | 0.00% | — | — | — | 10.00 | CO | Illinois corporation | 2018-04-27 | ↗ |
| 21 | Empery Asset Management, LP | — | 0.00% | — | — | — | — | PN | United States | 2017-01-31 | ↗ |
| 22 | George W. Haywood | — | 0.00% | — | — | — | — | IN | U.S.A. | 2007-02-14 | ↗ |
| 23 | Martin D. Hoe | — | 0.00% | — | — | — | — | IN | United States | 2017-01-31 | ↗ |
| 24 | Ryan M. Lane | — | 0.00% | — | — | — | — | IN | United States | 2017-01-31 | ↗ |
| 25 | Steven Boyd | — | 0.00% | — | — | — | — | HC, IN | Delaware | 2020-04-06 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
0
Sells
1
Shares acquired
—
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+0
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-06-28 | Xu Xiaochun | Director / Officer / 10% Owner | C-Conversion | A | Common Stock | 7,894,737 | 0.38 | 3.00M | 12,335,016 | — | ↗ |
| 2024-03-15 | Xu Xiaochun | Director / Officer / 10% Owner | C-Conversion | A | Common Stock | 4,113,158 | 0.38 | 1.56M | 4,440,279 | — | ↗ |
| 2023-11-17 | Xu Xiaochun | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 600,000 | 1.02 | 612.0K | 327,121 | — | ↗ |
| 2023-09-28 | Xu Xiaochun | Director / Officer / 10% Owner | C-Conversion | A | Common Stock | 654,206 | 1.07 | 700.0K | 927,121 | — | ↗ |
| 2023-07-14 | Xu James | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-07-14 | Xi Biao | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-06-28 | Boyalife Asset Holding II, Inc. | Director | C-Conversion | D | Second Amended and Restated Convertible Note | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-06-21 | LIU VIVIAN H | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-01-13 | Zhu Haihong | Director | — | D | Stock Option | 5,000 | 30.00 | 150.0K | 0 | — | ↗ |
| 2021-05-27 | Xu Xiaochun | Director | D-Return | D | Stock Option | 240,000 | 5.94 | 1.43M | 0 | — | ↗ |
| 2021-05-27 | Cauble Jeffery | Officer | D-Return | D | Stock Option | 40,000 | 5.94 | 237.6K | 0 | — | ↗ |
| 2020-06-04 | Xu Xiaochun | Director / Officer / 10% Owner | A-Award | A | Stock Option | 240,000 | 5.94 | 1.43M | 240,000 | — | ↗ |
| 2020-06-04 | Westgate Mark | Director | A-Award | A | Stock Option | 10,000 | 5.94 | 59.4K | 10,000 | — | ↗ |
| 2020-06-04 | MEDFORD RUSSELL M | Director | A-Award | A | Stock Option | 10,000 | 5.94 | 59.4K | 10,000 | — | ↗ |
| 2020-06-04 | JOSEPH THOMIS | Director | A-Award | A | Stock Option | 10,000 | 5.94 | 59.4K | 10,000 | — | ↗ |
| 2020-06-04 | Donaghy Debra | Director | A-Award | A | Stock Option | 10,000 | 5.94 | 59.4K | 10,000 | — | ↗ |
| 2020-06-04 | Cauble Jeffery | Officer | A-Award | A | Stock Option | 40,000 | 5.94 | 237.6K | 40,000 | — | ↗ |
| 2020-04-28 | Xu Xiaochun | Director / Officer / 10% Owner | J-Other | D | Common Stock | 621,637 | 1.80 | 1.12M | 1,728,857 | — | ↗ |
| 2020-02-13 | Xu Xiaochun | Director / Officer / 10% Owner | C-Conversion | A | Common Stock | 1,666,670 | 1.80 | 3.00M | 2,350,494 | — | ↗ |
| 2019-12-31 | Donaghy Debra | Director | — | D | Stock Options | 1,250 | 4.40 | 5.5K | 0 | — | ↗ |
| 2019-12-26 | Xu Xiaochun | Director / Officer / 10% Owner | P-Purchase | D | Warrants to Purchase Common Stock | 352,942 | 80.00 | 28.24M | 0 | — | ↗ |
| 2019-12-20 | Xu Xiaochun | Director / Officer / 10% Owner | J-Other | D | Participation Interest in Convertible Note | 0 | 1.80 | — | 0 | — | ↗ |
| 2019-09-16 | Westgate Mark | Director | A-Award | A | Stock Option | 3,400 | 4.38 | 14.9K | 3,400 | — | ↗ |
| 2019-09-16 | MEDFORD RUSSELL M | Director | A-Award | A | Stock Option | 3,400 | 4.38 | 14.9K | 3,400 | — | ↗ |
| 2019-09-16 | JOSEPH THOMIS | Director | A-Award | A | Stock Option | 3,400 | 4.38 | 14.9K | 3,400 | — | ↗ |
| 2018-12-14 | Xu Xiaochun | Director / Officer / 10% Owner | A-Award | A | Stock Option | 640,000 | 0.30 | 190.7K | 640,000 | — | ↗ |
| 2018-09-04 | JOSEPH THOMIS | Director | J-Other | D | Common Stock | 35,000 | 6,300.00 | 220.50M | 0 | — | ↗ |
| 2018-06-22 | Xu James | Director / Officer | A-Award | A | Stock Option | 13,500 | 0.44 | 5.9K | 13,500 | — | ↗ |
| 2018-04-16 | Xu Xiaochun | Director / Officer / 10% Owner | A-Award | A | Second Amended and Restated Convertible Promissory Note | 0 | 1.61 | — | 10,000,000 | — | ↗ |
| 2018-04-16 | Xu James | Director | D-Return | D | Stock Options | 34,000 | 3.00 | 102.0K | 20,000 | — | ↗ |
| 2018-04-16 | Westgate Mark | Director | D-Return | D | Stock Options | 34,000 | 3.00 | 102.0K | 20,000 | — | ↗ |
| 2018-04-16 | Li Yishu | 10% Owner | A-Award | A | Second Amended and Restated Convertible Promissory Note | 0 | 1.61 | — | 0 | — | ↗ |
| 2018-04-16 | JOSEPH THOMIS | Director | D-Return | D | Stock Options | 34,000 | 3.00 | 102.0K | 20,000 | — | ↗ |
| 2018-04-16 | Boyalife Asset Holding II, Inc. | 10% Owner | — | D | Second Amended and Restated Convertible Promissory Note | 6,211,180 | 1.61 | 10.00M | 0 | — | ↗ |
| 2018-03-09 | Xu James | Director | A-Award | A | Stock Options | 54,000 | 3.00 | 162.0K | 54,000 | — | ↗ |
| 2018-03-09 | Westgate Mark | Director | A-Award | A | Stock Options | 54,000 | 3.00 | 162.0K | 54,000 | — | ↗ |
| 2018-03-09 | MEDFORD RUSSELL M | Director | A-Award | A | Stock Options | 54,000 | 3.00 | 162.0K | 54,000 | — | ↗ |
| 2018-03-09 | JOSEPH THOMIS | Director | A-Award | A | Stock Options | 54,000 | 3.00 | 162.0K | 54,000 | — | ↗ |
| 2017-12-29 | Xu Xiaochun | Director / Officer / 10% Owner | A-Award | A | Stock Options | 300,000 | 3.00 | 900.0K | 300,000 | — | ↗ |
| 2017-12-29 | LIU VIVIAN H | Director / Officer | A-Award | A | Stock Options | 250,000 | 3.00 | 750.0K | 250,000 | — | ↗ |
| 2017-07-01 | Cauble Jeffery | Officer | A-Award | A | Common Stock | 9,320 | 3.17 | 29.5K | 9,320 | — | ↗ |
| 2017-05-10 | Xu James | Director | A-Award | A | Stock Options | 13,500 | 3.19 | 43.1K | 13,500 | — | ↗ |
| 2017-05-10 | Westgate Mark | Director | A-Award | A | Stock Options | 13,500 | 3.19 | 43.1K | 13,500 | — | ↗ |
| 2017-05-10 | Rao Mahendra S. | Director | A-Award | A | Stock Options | 13,500 | 3.19 | 43.1K | 13,500 | — | ↗ |
| 2017-05-10 | MEDFORD RUSSELL M | Director | A-Award | A | Stock Options | 12,250 | 3.19 | 39.1K | 12,250 | — | ↗ |
| 2017-05-10 | JOSEPH THOMIS | Director | A-Award | A | Stock Options | 12,250 | 3.19 | 39.1K | 12,250 | — | ↗ |
| 2017-03-28 | Ellner Kimberly Kay | Officer | A-Award | D | Common Stock | 2,338 | 3.15 | 7.4K | 1,699 | — | ↗ |
| 2017-03-27 | Ellner Kimberly Kay | Officer | A-Award | D | Common Stock | 162 | 3.15 | 510.30 | 4,037 | — | ↗ |
| 2017-03-10 | Cauble Jeffery | Officer | — | D | Common Stock (Restricted) | 0 | 0.00 | — | 90 | — | ↗ |
| 2017-02-24 | MEDFORD RUSSELL M | Director | — | D | Stock Options | 1,250 | 2.89 | 3.6K | 0 | — | ↗ |
| 2017-02-24 | LIU VIVIAN H | Director / Officer | A-Award | A | Common Stock | 25,000 | 2.89 | 72.3K | 25,000 | — | ↗ |
| 2017-01-10 | JOSEPH THOMIS | Director | — | D | Stock Options | 1,250 | 3.22 | 4.0K | 0 | — | ↗ |
| 2016-12-26 | Boyalife (Hong Kong) Ltd | 10% Owner | P-Purchase | A | Common Stock | 6,102,942 | 2.52 | 15.38M | 6,838,237 | — | ↗ |
| 2016-12-14 | Xu Xiaochun | Director / Officer / 10% Owner | A-Award | A | Stock Options | 50,000 | 2.91 | 145.5K | 50,000 | — | ↗ |
| 2016-11-03 | Xu James | Director | — | D | Stock Options | 1,250 | 2.84 | 3.6K | 0 | — | ↗ |
| 2016-11-03 | LIU VIVIAN H | Director | — | D | Stock Options | 1,250 | 2.84 | 3.6K | 0 | — | ↗ |
| 2016-09-28 | Ellner Kimberly Kay | Officer | A-Award | D | Common Stock | 502 | 3.98 | 2.0K | 7,199 | — | ↗ |
| 2016-08-22 | Xu Xiaochun | Director / 10% Owner | A-Award | A | Common Stock | 6,102,941 | 3.40 | 20.75M | 6,838,236 | — | ↗ |
| 2016-08-22 | Boyalife Investment Inc. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 6,102,941 | — | ↗ |
| 2016-07-26 | STRACEY ROBIN C | Director / Officer | A-Award | A | Common Stock | 29,720 | 0.00 | — | 116,676 | — | ↗ |
| 2016-07-26 | Ellner Kimberly Kay | Officer | A-Award | A | Common Stock | 12,997 | 0.00 | — | 20,818 | — | ↗ |
| 2016-07-26 | BRUCH MICHAEL | Officer | A-Award | A | Common Stock | 15,734 | 0.00 | — | 30,688 | — | ↗ |
| 2016-07-07 | STRACEY ROBIN C | Director / Officer | A-Award | A | Stock Options | 60,000 | 2.86 | 171.6K | 60,000 | — | ↗ |
| 2016-07-07 | Ellner Kimberly Kay | Officer | A-Award | A | Stock Options | 16,000 | 2.86 | 45.8K | 16,000 | — | ↗ |
| 2016-07-07 | BRUCH MICHAEL | Officer | A-Award | A | Common Stock | 14,603 | 2.86 | 41.8K | 20,165 | — | ↗ |
| 2016-07-01 | Xu Xiaochun | Director | A-Award | A | Stock Options | 1,250 | 2.86 | 3.6K | 1,250 | — | ↗ |
| 2016-07-01 | Rhein Denis Michael | Director | A-Award | A | Stock Options | 1,250 | 2.86 | 3.6K | 3,750 | — | ↗ |
| 2016-07-01 | Rao Mahendra S. | Director | A-Award | A | Stock Options | 1,250 | 2.86 | 3.6K | 5,000 | — | ↗ |
| 2016-07-01 | MOORE CRAIG W | Director | A-Award | A | Stock Options | 1,250 | 2.86 | 3.6K | 4,500 | — | ↗ |
| 2016-07-01 | Bagnall Mark | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-04-01 | Rhein Denis Michael | Director | A-Award | A | Common Stock | 912 | 4.01 | 3.7K | 27,221 | — | ↗ |
| 2016-04-01 | Rao Mahendra S. | Director | A-Award | A | Common Stock | 1,746 | 4.01 | 7.0K | 2,807 | — | ↗ |
| 2016-04-01 | MOORE CRAIG W | Director | A-Award | A | Common Stock | 1,239 | 4.01 | 5.0K | 6,051 | — | ↗ |
| 2016-03-09 | Xu Xiaochun | Director | A-Award | A | Stock Options | 1,250 | 4.20 | 5.3K | 1,250 | — | ↗ |
| 2016-03-09 | Ellner Kimberly Kay | Officer | — | D | Stock Options | 750 | 12.60 | 9.5K | 0 | — | ↗ |
| 2016-02-13 | Li Yishu | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 14,705,882 | — | ↗ |
| 2015-11-10 | Harris Kenneth | 10% Owner | S-Sale | D | Common Stock | 2,200 | 0.60 | 1.3K | 4,490,410 | — | ↗ |
| 2015-11-09 | Harris Kenneth | 10% Owner | S-Sale | D | Common Stock | 48,468 | 0.60 | 29.1K | 4,492,610 | — | ↗ |
| 2015-11-06 | Harris Kenneth | 10% Owner | S-Sale | D | Common Stock | 30,190 | 0.60 | 18.1K | 4,541,078 | — | ↗ |
| 2015-10-29 | Harris Kenneth | 10% Owner | S-Sale | D | Common Stock | 8,632 | 0.60 | 5.2K | 4,581,778 | — | ↗ |
| 2015-10-22 | BRUCH MICHAEL | Officer | A-Award | A | Stock Options | 50,000 | 0.60 | 30.0K | 100,000 | — | ↗ |
| 2015-09-30 | Rao Mahendra S. | Director | A-Award | A | Common Stock | 7,075 | 0.53 | 3.7K | 21,209 | — | ↗ |
| 2015-09-30 | MOORE CRAIG W | Director | A-Award | A | Common Stock | 9,375 | 0.53 | 5.0K | 96,223 | — | ↗ |
| 2015-09-28 | Harris Kenneth | 10% Owner | A-Award | A | Option | 270,000 | 0.60 | 162.0K | 530,000 | — | ↗ |
| 2015-09-17 | BRUCH MICHAEL | Officer | F-InKind | D | Common Stock | 9,915 | 0.65 | 6.4K | 114,827 | — | ↗ |
| 2015-09-10 | BRUCH MICHAEL | Officer | A-Award | A | Option | 50,000 | 0.63 | 31.5K | 50,000 | — | ↗ |
| 2015-09-02 | Plavan Matthew T | Officer | S-Sale | D | Common Stock | 11,400 | 0.68 | 7.8K | 250,937 | — | ↗ |
| 2015-07-01 | Rhein Denis Michael | Director | A-Award | D | Option | 25,000 | 0.81 | 20.2K | 50,000 | — | ↗ |
| 2015-07-01 | MOORE CRAIG W | Director | A-Award | A | Option | 25,000 | 0.81 | 20.2K | 80,000 | — | ↗ |
| 2015-06-30 | MOORE CRAIG W | Director | A-Award | A | Common Stock | 5,846 | 0.85 | 5.0K | 86,848 | — | ↗ |
| 2015-06-09 | STRACEY ROBIN C | Director / Officer | A-Award | A | Option | 1,000,000 | 0.83 | 832.0K | 1,065,000 | — | ↗ |
| 2015-05-09 | BRUCH MICHAEL | Officer | — | D | Common Stock (Restricted) | 0 | 0.00 | — | 10,791 | — | ↗ |
| 2015-03-31 | Rao Mahendra S. | Director | A-Award | A | Common Stock | 9,722 | 0.90 | 8.7K | 9,722 | — | ↗ |
| 2015-03-31 | MOORE CRAIG W | Director | A-Award | A | Common Stock | 5,799 | 0.90 | 5.2K | 81,002 | — | ↗ |
| 2015-02-18 | Sivilotti Mitchel | 10% Owner | F-InKind | D | Common Stock | 6,692 | 0.88 | 5.9K | 4,660,539 | — | ↗ |
| 2015-02-18 | Harris Kenneth | Director / Officer / 10% Owner | F-InKind | D | Common Stock | 6,692 | 0.88 | 5.9K | 4,590,410 | — | ↗ |
| 2014-12-31 | MOORE CRAIG W | Director | A-Award | A | Common Stock | 5,116 | 1.02 | 5.2K | 75,203 | — | ↗ |
| 2014-12-05 | Plavan Matthew T | Director | F-InKind | D | Common Stock | 23,765 | 1.05 | 25.0K | 262,337 | — | ↗ |
| 2014-12-01 | Rhein Denis Michael | Director | — | D | Option | 25,000 | 1.02 | 25.5K | 0 | — | ↗ |
| 2014-12-01 | BESSEY DAN T | Officer | A-Award | A | Option | 150,000 | 1.02 | 153.0K | 393,585 | — | ↗ |
| 2014-09-30 | STRACEY ROBIN C | Director | A-Award | A | Common Stock | 5,738 | 1.22 | 7.0K | 50,405 | — | ↗ |
| 2014-09-30 | MOORE CRAIG W | Director | A-Award | A | Common Stock | 8,555 | 1.22 | 10.4K | 70,087 | — | ↗ |
| 2014-08-19 | Sivilotti Mitchel | 10% Owner | A-Award | A | Option | 80,000 | 1.31 | 104.8K | 180,000 | — | ↗ |
| 2014-08-19 | Plavan Matthew T | Director / Officer | A-Award | A | Option | 400,000 | 1.31 | 524.0K | 762,500 | — | ↗ |
| 2014-08-19 | Pappa Kenneth | Officer | A-Award | A | Option | 80,000 | 1.31 | 104.8K | 136,200 | — | ↗ |
| 2014-08-19 | Harris Kenneth | Director / Officer / 10% Owner | A-Award | A | Option | 160,000 | 1.31 | 209.6K | 260,000 | — | ↗ |
| 2014-08-19 | BESSEY DAN T | Officer | A-Award | A | Option | 160,000 | 1.31 | 209.6K | 243,585 | — | ↗ |
| 2014-07-29 | Plavan Matthew T | Director / Officer | F-InKind | D | Common Stock | 8,488 | 1.39 | 11.8K | 293,602 | — | ↗ |
| 2014-07-29 | Pappa Kenneth | Officer | F-InKind | D | Common Stock | 5,508 | 1.39 | 7.7K | 86,575 | — | ↗ |
| 2014-07-01 | STRACEY ROBIN C | Director | A-Award | A | Option | 25,000 | 1.38 | 34.5K | 65,000 | — | ↗ |
| 2014-07-01 | Rao Mahendra S. | Director | A-Award | A | Option | 25,000 | 1.38 | 34.5K | 50,000 | — | ↗ |
| 2014-07-01 | MOORE CRAIG W | Director | A-Award | A | Option | 25,000 | 1.38 | 34.5K | 95,000 | — | ↗ |
| 2014-07-01 | MCENANY PATRICK J | Director | A-Award | A | Option | 25,000 | 1.38 | 34.5K | 122,750 | — | ↗ |
| 2014-06-30 | STRACEY ROBIN C | Director | A-Award | A | Common Stock | 5,036 | 1.39 | 7.0K | 44,667 | — | ↗ |
| 2014-06-30 | MOORE CRAIG W | Director | A-Award | A | Common Stock | 7,509 | 1.39 | 10.4K | 61,532 | — | ↗ |
| 2014-06-01 | Plavan Matthew T | Director / Officer | F-InKind | D | Common Stock | 3,395 | 1.71 | 5.8K | 302,090 | — | ↗ |
| 2014-04-01 | Rao Mahendra S. | Director | — | D | Option | 25,000 | 1.78 | 44.5K | 0 | — | ↗ |
| 2014-03-31 | MOORE CRAIG W | Director | A-Award | A | Common Stock | 6,140 | 1.70 | 10.4K | 54,023 | — | ↗ |
| 2014-03-03 | Plavan Matthew T | Director / Officer | A-Award | A | Option | 100,000 | 2.18 | 218.0K | 362,500 | — | ↗ |
| 2014-03-03 | Pappa Kenneth | Officer | A-Award | A | Option | 18,700 | 2.18 | 40.8K | 56,200 | — | ↗ |
| 2014-03-03 | BESSEY DAN T | Officer | A-Award | A | Option | 33,585 | 2.18 | 73.2K | 83,585 | — | ↗ |
| 2014-03-03 | BAKER HAROLD | Officer | A-Award | A | Common Stock | 37,500 | 0.00 | — | 76,867 | — | ↗ |
| 2014-02-18 | Sivilotti Mitchel | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 4,617,231 | — | ↗ |
| 2014-02-18 | Harris Kenneth | Director / Officer / 10% Owner | — | D | Common Stock (Restricted) | 0 | 0.00 | — | 50,000 | — | ↗ |
| 2013-12-31 | STRACEY ROBIN C | Director | A-Award | A | Common Stock | 9,070 | 1.02 | 9.3K | 33,160 | — | ↗ |
| 2013-12-31 | MOORE CRAIG W | Director | A-Award | A | Common Stock | 5,393 | 1.02 | 5.5K | 47,883 | — | ↗ |
| 2013-09-30 | STRACEY ROBIN C | Director | A-Award | A | Common Stock | 7,870 | 1.08 | 8.5K | 24,090 | — | ↗ |
| 2013-09-30 | MOORE CRAIG W | Director | A-Award | A | Common Stock | 5,093 | 1.08 | 5.5K | 42,490 | — | ↗ |
| 2013-07-29 | Plavan Matthew T | Director / Officer | F-InKind | D | Common Stock | 8,402 | 1.16 | 9.7K | 95,485 | — | ↗ |
| 2013-07-29 | Pappa Kenneth | Officer | F-InKind | D | Common Stock | 5,508 | 1.16 | 6.4K | 54,584 | — | ↗ |
| 2013-07-01 | STRACEY ROBIN C | Director | A-Award | A | Option | 15,000 | 1.37 | 20.6K | 40,000 | — | ↗ |
| 2013-07-01 | MOORE CRAIG W | Director | A-Award | A | Option | 15,000 | 1.37 | 20.6K | 76,250 | — | ↗ |
| 2013-07-01 | MCENANY PATRICK J | Director | A-Award | A | Option | 15,000 | 1.37 | 20.6K | 109,000 | — | ↗ |
| 2013-06-28 | STRACEY ROBIN C | Director | A-Award | A | Common Stock | 10,926 | 1.35 | 14.8K | 16,220 | — | ↗ |
| 2013-06-28 | MOORE CRAIG W | Director | A-Award | A | Common Stock | 5,926 | 1.35 | 8.0K | 37,397 | — | ↗ |
| 2013-06-01 | Plavan Matthew T | Director / Officer | F-InKind | D | Common Stock | 3,300 | 1.17 | 3.9K | 103,887 | — | ↗ |
| 2013-03-28 | STRACEY ROBIN C | Director | A-Award | A | Common Stock | 5,294 | 0.85 | 4.5K | 5,294 | — | ↗ |
| 2013-03-28 | MOORE CRAIG W | Director | A-Award | A | Common Stock | 6,471 | 0.85 | 5.5K | 31,471 | — | ↗ |
| 2013-03-27 | BESSEY DAN T | Officer | — | D | Common Stock | 0 | 0.00 | — | 50,000 | — | ↗ |
| 2012-07-30 | Plavan Matthew T | Director / Officer | A-Award | A | Option | 162,500 | 0.93 | 150.3K | 325,000 | — | ↗ |
| 2012-07-29 | Plavan Matthew T | Director / Officer | F-InKind | D | Common Stock | 8,263 | 0.88 | 7.3K | 107,187 | — | ↗ |
| 2012-07-29 | Pappa Kenneth | Officer | F-InKind | D | Common Stock | 5,508 | 0.88 | 4.8K | 60,092 | — | ↗ |
| 2012-07-02 | MOORE CRAIG W | Director | A-Award | A | Option | 15,000 | 0.90 | 13.5K | 61,250 | — | ↗ |
| 2012-07-02 | MCENANY PATRICK J | Director | A-Award | A | Option | 15,000 | 0.90 | 13.5K | 100,500 | — | ↗ |
| 2012-07-02 | CARTER DAVID WARREN | Director | A-Award | A | Option | 15,000 | 0.90 | 13.5K | 61,250 | — | ↗ |
| 2012-06-01 | Plavan Matthew T | Director / Officer | F-InKind | D | Common Stock | 3,300 | 0.87 | 2.9K | 115,450 | — | ↗ |
| 2012-01-30 | Cooksy Kevin | Officer | — | D | Common Stock | 0 | 0.00 | — | 50,000 | — | ↗ |
| 2012-01-27 | MOORE CRAIG W | Director | A-Award | A | Common Stock | 25,000 | 1.02 | 25.5K | 25,000 | — | ↗ |
| 2011-10-28 | HARGREAVES KAREN AUDITORE | Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2011-10-12 | Pappa Kenneth | Officer | — | D | Stock Option | 18,750 | 2.54 | 47.6K | 0 | — | ↗ |
| 2011-10-10 | HARGREAVES KAREN AUDITORE | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2011-07-29 | STRACEY ROBIN C | Director | — | D | Option | 25,000 | 1.98 | 49.5K | 0 | — | ↗ |
| 2011-07-29 | Rao Mahendra S. | Director | G-Gift | D | Options | 15,000 | 2.03 | 30.5K | 0 | — | ↗ |
| 2011-07-29 | Plavan Matthew T | Officer | A-Award | A | Common Stock | 75,000 | 0.00 | — | 118,750 | — | ↗ |
| 2011-07-29 | ENGLE J MELVILLE | Director / Officer | A-Award | A | Common Stock | 100,000 | 0.00 | — | 172,500 | — | ↗ |
| 2011-07-29 | ARTILES JORGE | Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 50,100 | — | ↗ |
| 2011-07-01 | Rao Mahendra S. | Director | A-Award | A | Options | 15,000 | 2.03 | 30.5K | 53,750 | — | ↗ |
| 2011-07-01 | MOORE CRAIG W | Director | A-Award | A | Options | 15,000 | 2.03 | 30.5K | 46,250 | — | ↗ |
| 2011-07-01 | MCENANY PATRICK J | Director | A-Award | A | Options | 15,000 | 2.03 | 30.5K | 89,250 | — | ↗ |
| 2011-07-01 | HUCKEL HUBERT E MD | Director | A-Award | A | Options | 15,000 | 2.03 | 30.5K | 70,500 | — | ↗ |
| 2011-06-01 | Plavan Matthew T | Officer | A-Award | A | Common Stock | 30,000 | 2.25 | 67.5K | 43,750 | — | ↗ |
| 2011-03-10 | ENGLE J MELVILLE | Director / Officer | P-Purchase | A | Common Stock | 22,500 | 2.30 | 51.8K | 72,500 | — | ↗ |
| 2011-02-15 | SHAVIT MENACHEM | Officer | A-Award | A | Option | 37,500 | 2.88 | 108.0K | 105,000 | — | ↗ |
| 2011-02-15 | ENGLE J MELVILLE | Director / Officer | A-Award | A | Option | 62,500 | 2.88 | 180.0K | 350,000 | — | ↗ |
| 2011-02-15 | BAKER HAROLD | Officer | A-Award | A | Option | 37,500 | 2.88 | 108.0K | 100,000 | — | ↗ |
| 2011-02-15 | ARTILES JORGE | Officer | A-Award | A | Option | 37,500 | 2.88 | 108.0K | 100,000 | — | ↗ |
| 2010-12-10 | MCENANY PATRICK J | Director | A-Award | A | Option | 25,000 | 2.56 | 64.0K | 74,250 | — | ↗ |
| 2010-10-29 | Rao Mahendra S. | Director | A-Award | A | Option | 25,000 | 3.03 | 75.8K | 38,750 | — | ↗ |
| 2010-10-29 | MOORE CRAIG W | Director | A-Award | A | Option | 25,000 | 3.03 | 75.8K | 31,250 | — | ↗ |
| 2010-10-29 | MCENANY PATRICK J | Director | A-Award | A | Option | 25,000 | 3.03 | 75.8K | 49,250 | — | ↗ |
| 2010-10-29 | HUCKEL HUBERT E MD | Director | A-Award | A | Option | 25,000 | 3.03 | 75.8K | 55,500 | — | ↗ |
| 2010-10-29 | CARTER DAVID WARREN | Director | A-Award | A | Option | 25,000 | 3.03 | 75.8K | 31,250 | — | ↗ |
| 2010-07-01 | Rao Mahendra S. | Director | A-Award | A | Option | 15,000 | 0.47 | 7.1K | 55,000 | — | ↗ |
| 2010-07-01 | MCENANY PATRICK J | Director | A-Award | A | Option | 15,000 | 0.47 | 7.1K | 97,000 | — | ↗ |
| 2010-07-01 | HUCKEL HUBERT E MD | Director | A-Award | A | Option | 15,000 | 0.47 | 7.1K | 122,000 | — | ↗ |
| 2010-06-12 | Pappa Kenneth | Officer | — | D | Stock Option | 1,250 | 17.68 | 22.1K | 0 | — | ↗ |
| 2010-06-10 | SHAVIT MENACHEM | Officer | A-Award | A | Option | 150,000 | 0.58 | 87.0K | 270,000 | — | ↗ |
| 2010-06-10 | Plavan Matthew T | Officer | A-Award | A | Option | 200,000 | 0.58 | 116.0K | 815,000 | — | ↗ |
| 2010-06-10 | ENGLE J MELVILLE | Director / Officer | A-Award | A | Option | 250,000 | 0.58 | 145.0K | 950,000 | — | ↗ |
| 2010-06-10 | BAKER HAROLD | Officer | A-Award | A | Option | 150,000 | 0.58 | 87.0K | 250,000 | — | ↗ |
| 2010-06-10 | ARTILES JORGE | Officer | A-Award | A | Option | 150,000 | 0.58 | 87.0K | 250,000 | — | ↗ |
| 2010-05-16 | Pappa Kenneth | Officer | — | D | Stock Option | 244 | 11.52 | 2.8K | 0 | — | ↗ |
| 2010-05-04 | CARTER DAVID WARREN | Director | — | D | Option | 25,000 | 0.80 | 20.0K | 0 | — | ↗ |
| 2010-01-13 | ARTILES JORGE | Officer | P-Purchase | A | Common Stock | 100 | 0.59 | 59.00 | 400 | — | ↗ |
| 2010-01-11 | ARTILES JORGE | Officer | P-Purchase | A | Common Stock | 300 | 0.61 | 183.00 | 300 | — | ↗ |
| 2009-12-07 | MOORE CRAIG W | Director | — | D | Option | 25,000 | 0.63 | 15.8K | 0 | — | ↗ |
| 2009-10-19 | ARTILES JORGE | Officer | — | D | Option | 100,000 | 0.67 | 67.0K | 0 | — | ↗ |
| 2009-09-25 | ENGLE J MELVILLE | Director / Officer | P-Purchase | A | Common Stock | 100,000 | 0.57 | 57.0K | 200,000 | — | ↗ |
| 2009-08-10 | BAKER HAROLD | Officer | — | D | Option | 100,000 | 0.72 | 72.0K | 0 | — | ↗ |
| 2009-07-30 | Plavan Matthew T | Officer | A-Award | A | Option | 100,000 | 0.64 | 63.5K | 615,000 | — | ↗ |
| 2009-07-30 | Chapman John | Officer | A-Award | A | Option | 85,000 | 0.64 | 54.0K | 295,000 | — | ↗ |
| 2009-07-01 | Rao Mahendra S. | Director | A-Award | A | Option | 15,000 | 0.63 | 9.5K | 40,000 | — | ↗ |
| 2009-07-01 | MYERS WOODROW A JR | Director | A-Award | A | Option | 15,000 | 0.63 | 9.5K | 70,000 | — | ↗ |
| 2009-07-01 | MCENANY PATRICK J | Director | A-Award | A | Option | 15,000 | 0.63 | 9.5K | 82,000 | — | ↗ |
| 2009-07-01 | HUCKEL HUBERT E MD | Director | A-Award | A | Option | 15,000 | 0.63 | 9.5K | 107,000 | — | ↗ |
| 2009-05-12 | ENGLE J MELVILLE | Officer | P-Purchase | A | Common Stock | 100,000 | 0.55 | 55.0K | 100,000 | — | ↗ |
| 2009-05-08 | MCENANY PATRICK J | Director | P-Purchase | A | Common Stock | 25,000 | 0.53 | 13.3K | 82,329 | — | ↗ |
| 2009-04-16 | ENGLE J MELVILLE | Officer | — | D | Option | 700,000 | 0.58 | 405.3K | 0 | — | ↗ |
| 2009-01-30 | SHAVIT MENACHEM | Officer | A-Award | A | Options | 70,000 | 0.77 | 53.9K | 120,000 | — | ↗ |
| 2009-01-30 | SCHNOLL LESLIE | Officer | A-Award | A | Options | 70,000 | 0.77 | 53.9K | 120,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-355.5K
Shares Outstanding
15.85M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2022 | Chris Xu, Ph.D., MBA Chief Executive Officer | 519.0K | 180.0K | — | — | — | — | 699.0K | 0.00% | ↗ |
| 2 | 2022 | Haihong Zhu Chief Operating Officer | 458.0K | 96.0K | — | — | — | — | 554.0K | 0.00% | ↗ |
| 3 | 2022 | Jeffery Cauble, CPA Chief Financial Officer | 264.0K | 61.0K | — | — | — | — | 325.0K | 0.00% | ↗ |
| 4 | 2021 | Chris Xu, Ph.D., MBA Chief Executive Officer | 500.0K | 248.0K | — | — | — | — | 748.0K | 0.00% | ↗ |
| 5 | 2021 | Jeffery Cauble, CPA Chief Financial Officer | 254.0K | 95.0K | — | — | — | — | 349.0K | 0.00% | ↗ |
| 6 | 2020 | Chris Xu, Ph.D., MBA Chief Executive Officer | 505.0K | 276.0K | — | 1.22M | — | — | 2.00M | 60.89% | ↗ |
| 7 | 2020 | Jeffery Cauble, CPA Chief Financial Officer | 244.0K | — | — | 203.0K | — | — | 447.0K | 45.41% | ↗ |
| 8 | 2019 | Chris Xu, Ph.D. Chief Executive Officer | 472.0K | — | — | — | — | — | 472.0K | 0.00% | ↗ |
| 9 | 2019 | Chris Xu, Ph.D., MBA Chief Executive Officer | 472.0K | — | — | — | — | — | 472.0K | 0.00% | ↗ |
| 10 | 2019 | Jeffery Cauble, CPA Chief Financial Officer | 179.0K | 43.0K | — | — | — | — | 222.0K | 0.00% | ↗ |
| 11 | 2019 | Jeff Cauble , CPA Chief Financial Officer | 179.0K | 43.0K | — | — | — | — | 222.0K | 0.00% | ↗ |
| 12 | 2019 | James Xu Former General Counsel, Sr. VP of Legal Affairs and Cybersecurity (until 12/31/19) | 99.0K | — | — | — | — | — | 99.0K | 0.00% | ↗ |
| 13 | 2018 | Chris Xu, Ph.D. Chief Executive Officer | 460.0K | — | — | 193.0K | — | — | 653.0K | 29.56% | ↗ |
| 14 | 2018 | Vivian Liu Former COO (until | 212.0K | — | — | — | — | 7.00 | 266.0K | 0.00% | ↗ |
| 15 | 2018 | Jeff Cauble , CPA Chief Financial Officer | 160.0K | — | 1.0K | 48.0K | — | — | 209.0K | 23.44% | ↗ |
| 16 | 2018 | Jeff Cauble Principal Financial & | 160.0K | — | 1.0K | 48.0K | — | — | 209.0K | 23.44% | ↗ |
| 17 | 2018 | James Xu General Counsel, Sr. Vice President of Legal Affairs and Cybersecurity | 53.0K | — | — | 70.0K | — | 7.0K | 130.0K | 53.85% | ↗ |
| 18 | 2018 | James Xu Former General Counsel, Sr. VP of Legal Affairs and Cybersecurity (until 12/31/19) | 53.0K | — | — | 70.0K | — | 7.0K | 130.0K | 53.85% | ↗ |
| 19 | 2017 | Chris Xu, Ph.D. Chief Executive Officer | 216.0K | — | — | 706.0K | — | 26.0K | 948.0K | 74.47% | ↗ |
| 20 | 2017 | Vivian Liu Chief Operating Officer (as of 2/15/17) | 128.0K | — | — | 58.9K | — | 26.0K | 743.0K | 7.93% | ↗ |
| 21 | 2017 | Vivian Liu Former COO (until | 128.0K | — | — | 589.0K | — | 26.0K | 743.0K | 79.27% | ↗ |
| 22 | 2017 | Chris Xu, Ph.D. Chief Executive Officer (as of 11/3/16) | 263.0K | — | — | 104.0K | — | — | 367.0K | 28.34% | ↗ |
| 23 | 2017 | Accounting Officer | 143.0K | 6.0K | 46.0K | 8.0K | — | — | 203.0K | 26.60% | ↗ |
| 24 | 2017 | Jeff Cauble Principal Financial & | 80.0K | 26.0K | — | — | — | — | 106.0K | 0.00% | ↗ |
| 25 | 2017 | Jeff Cauble Principal Financial & Accounting Officer (as of 3/10/17) | 80.0K | 26.0K | — | — | — | — | 106.0K | 0.00% | ↗ |
| 26 | 2017 | James Xu General Counsel, Sr. Vice President of Legal Affairs and Cybersecurity | — | — | — | 33.0K | — | 7.0K | 40.0K | 82.50% | ↗ |
| 27 | 2016 | Robin Stracey Former CEO (until 11/3/16) | 425.0K | — | — | — | 220.0K | 24.0K | 669.0K | 0.00% | ↗ |
| 28 | 2016 | Ken Harris Former President (until 9/28/15) | 85.0K | — | — | 32.0K | — | 293.0K | 410.0K | 7.80% | ↗ |
| 29 | 2016 | Michael Bruch Former CFO (until 3/10/17) | 204.0K | 20.0K | 13.0K | 35.0K | 56.0K | — | 328.0K | 14.63% | ↗ |
| 30 | 2016 | Kim Ellner VP, Manufacturing & Global Supply Chain | 164.0K | 6.0K | 3.0K | 16.0K | 46.0K | — | 235.0K | 8.09% | ↗ |
| 31 | 2016 | Mitchel Sivilotti Former Chief Biologist (until 12/14/15) | 119.0K | — | — | — | — | 71.0K | 190.0K | 0.00% | ↗ |
| 32 | 2016 | Jeff Cauble Principal Financial & Accounting Officer (as of 3/10/17) | 126.0K | 11.0K | 6.0K | 9.0K | 11.0K | — | 163.0K | 9.20% | ↗ |
| 33 | 2015 | Robin Stracey CEO as of October 29, 2014 | 283.0K | — | 832.0K | 465.0K | — | 1.0K | 1.58M | 82.04% | ↗ |
| 34 | 2015 | Robin Stracey Former CEO (until 11/3/16) | 283.0K | — | 832.0K | 465.0K | — | 1.0K | 1.58M | 82.04% | ↗ |
| 35 | 2015 | Matthew Plavan CEO thru October 28, 2014 | 142.0K | — | — | 304.0K | — | 560.0K | 1.01M | 30.22% | ↗ |
| 36 | 2015 | Dan Bessey CFO thru May 9, 2015 | 248.0K | — | — | 208.0K | — | 26.0K | 482.0K | 43.15% | ↗ |
| 37 | 2015 | Ken Harris Former President (until 9/28/15) | 329.0K | — | — | 122.0K | — | 12.0K | 463.0K | 26.35% | ↗ |
| 38 | 2015 | Ken Harris President thru September 28, 2015 | 329.0K | — | — | 122.0K | — | 12.0K | 463.0K | 26.35% | ↗ |
| 39 | 2015 | Mitchel Sivilotti Former Chief Biologist (until 12/14/15) | 240.0K | — | — | 61.0K | — | 12.0K | 313.0K | 19.49% | ↗ |
| 40 | 2015 | Mitchel Sivilotti Chief Biologist thru December 14, 2015 | 240.0K | — | — | 61.0K | — | 12.0K | 313.0K | 19.49% | ↗ |
| 41 | 2015 | Ray DeGrella VP, Quality & Regulatory Affairs thru September 10, 2015 | 250.0K | — | — | 61.0K | — | — | 311.0K | 19.61% | ↗ |
| 42 | 2015 | Michael Bruch Former CFO (until 3/10/17) | 157.0K | — | 53.0K | — | — | — | 210.0K | 25.24% | ↗ |
| 43 | 2015 | Michael Bruch Interim CFO as of May 9, 2015, CFO as of October 23, 2015 | 157.0K | — | 53.0K | — | — | — | 210.0K | 25.24% | ↗ |
| 44 | 2015 | Kim Ellner VP, Manufacturing & Global Supply Chain | 153.0K | 6.0K | — | — | — | — | 159.0K | 0.00% | ↗ |
| 45 | 2014 | Matthew Plavan CEO thru October 28, 2014 | 349.0K | 100.0K | 458.0K | 122.0K | — | — | 1.03M | 56.37% | ↗ |
| 46 | 2014 | Matthew Plavan Chief Executive Officer thru October 28, 2014 | 349.0K | 100.0K | 458.0K | 122.0K | — | — | 1.03M | 56.37% | ↗ |
| 47 | 2014 | Hal Baker Former V.P., Commercial Operations & Marketing | 211.0K | 75.0K | 82.0K | 23.0K | — | 160.0K | 551.0K | 19.06% | ↗ |
| 48 | 2014 | Dan Bessey Chief Financial Officer | 259.0K | 50.0K | 147.0K | 41.0K | — | — | 497.0K | 37.83% | ↗ |
| 49 | 2014 | Dan Bessey CFO thru May 9, 2015 | 259.0K | 50.0K | 147.0K | 41.0K | — | — | 497.0K | 37.83% | ↗ |
| 50 | 2014 | Ken Harris President thru September 28, 2015 | 96.0K | 40.0K | 109.0K | 121.0K | — | 4.0K | 370.0K | 62.16% | ↗ |
| 51 | 2014 | Ken Harris President | 96.0K | 40.0K | 109.0K | 121.0K | — | 4.0K | 370.0K | 62.16% | ↗ |
| 52 | 2014 | Ken Pappa V.P., Manufacturing and IT | 247.0K | 10.0K | 82.0K | 23.0K | — | — | 362.0K | 29.01% | ↗ |
| 53 | 2014 | Mitchel Sivilotti Chief Biologist thru December 14, 2015 | 74.0K | 40.0K | 109.0K | 121.0K | — | 4.0K | 348.0K | 66.09% | ↗ |
| 54 | 2014 | Mitchel Sivilotti Chief Biologist | 74.0K | 40.0K | 109.0K | 121.0K | — | 4.0K | 348.0K | 66.09% | ↗ |
| 55 | 2014 | Michael Bruch Interim CFO as of May 9, 2015, CFO as of October 23, 2015 | 157.0K | 30.0K | 15.0K | — | — | — | 202.0K | 7.43% | ↗ |
| 56 | 2014 | Ray DeGrella VP, Quality & Regulatory Affairs thru September 10, 2015 | 77.0K | — | 96.0K | — | — | — | 173.0K | 55.49% | ↗ |
| 57 | 2013 | Matthew Plavan Chief Executive Officer | 315.0K | — | — | 88.0K | — | — | 403.0K | 21.84% | ↗ |
| 58 | 2013 | Matthew Plavan Chief Executive Officer thru October 28, 2014 | 315.0K | — | — | 88.0K | — | — | 403.0K | 21.84% | ↗ |
| 59 | 2013 | Hal Baker V.P., Commercial Operations & Marketing | 263.0K | 99.0K | — | — | — | 8.0K | 370.0K | 0.00% | ↗ |
| 60 | 2013 | Hal Baker Former V.P., Commercial Operations & Marketing | 263.0K | 99.0K | — | — | — | 8.0K | 370.0K | 0.00% | ↗ |
| 61 | 2013 | Ken Pappa V.P., Engineering & Manufacturing | 245.0K | 25.0K | — | — | — | — | 270.0K | 0.00% | ↗ |
| 62 | 2013 | Ken Pappa V.P., Manufacturing and IT | 245.0K | 25.0K | — | — | — | — | 270.0K | 0.00% | ↗ |
| 63 | 2013 | Kevin Cooksy V.P., Corporate Development & Scientific Affairs | 240.0K | — | — | — | — | — | 240.0K | 0.00% | ↗ |
| 64 | 2013 | Dan Bessey Chief Financial Officer | 61.0K | — | 46.0K | 22.0K | — | — | 129.0K | 52.71% | ↗ |
| 65 | 2012 | J. Melville Engle Former Chief Executive Officer | 246.0K | 125.0K | 198.0K | — | — | 337.0K | 906.0K | 21.85% | ↗ |
| 66 | 2012 | Matthew Plavan Chief Executive Officer thru October 28, 2014 | 315.0K | — | 149.0K | — | — | — | 464.0K | 32.11% | ↗ |
| 67 | 2012 | Matthew Plavan Chief Executive Officer & Chief Financial Officer | 315.0K | — | 149.0K | — | — | — | 464.0K | 32.11% | ↗ |
| 68 | 2012 | Matthew Plavan Chief Executive Officer | 315.0K | — | 149.0K | — | — | — | 464.0K | 32.11% | ↗ |
| 69 | 2012 | Hal Baker V.P., Commercial Operations | 262.0K | 85.0K | 99.0K | — | — | 9.0K | 455.0K | 21.76% | ↗ |
| 70 | 2012 | Hal Baker V.P., Commercial Operations & Marketing | 262.0K | 85.0K | 99.0K | — | — | 9.0K | 455.0K | 21.76% | ↗ |
| 71 | 2012 | Hal Baker Former V.P., Commercial Operations & Marketing | 262.0K | 85.0K | 99.0K | — | — | 9.0K | 455.0K | 21.76% | ↗ |
| 72 | 2012 | Ken Pappa V.P., Manufacturing, Engineering and Quality | 239.0K | — | 99.0K | — | — | — | 338.0K | 29.29% | ↗ |
| 73 | 2012 | Ken Pappa V.P., Engineering & Manufacturing | 239.0K | — | 99.0K | — | — | — | 338.0K | 29.29% | ↗ |
| 74 | 2012 | Ken Pappa V.P., Manufacturing and IT | 239.0K | — | 99.0K | — | — | — | 338.0K | 29.29% | ↗ |
| 75 | 2012 | Kevin Cooksy V.P., Corporate Development , Scientific & Regulatory Affairs | 193.0K | 4.0K | 82.0K | — | — | — | 279.0K | 29.39% | ↗ |
| 76 | 2012 | Kevin Cooksy V.P., Corporate Development & Scientific Affairs | 193.0K | 4.0K | 82.0K | — | — | — | 279.0K | 29.39% | ↗ |
| 77 | 2011 | J. Melville Engle Chief Executive Officer | 350.0K | — | — | 210.0K | — | 17.0K | 577.0K | 36.40% | ↗ |
| 78 | 2011 | J. Melville Engle Former Chief Executive Officer | 350.0K | — | — | 210.0K | — | 17.0K | 577.0K | 36.40% | ↗ |
| 79 | 2011 | Matthew T. Plavan CFO & EVP, Business Development | 301.0K | 89.0K | 68.0K | 92.0K | — | — | 550.0K | 29.09% | ↗ |
| 80 | 2011 | Matthew Plavan Chief Executive Officer & Chief Financial Officer | 301.0K | 89.0K | 68.0K | 92.0K | — | — | 550.0K | 29.09% | ↗ |
| 81 | 2011 | Matthew Plavan Chief Executive Officer | 301.0K | 89.0K | 68.0K | 92.0K | — | — | 550.0K | 29.09% | ↗ |
| 82 | 2011 | Hal Baker V.P., Commercial Operations & Marketing | 250.0K | 178.0K | — | 69.0K | — | 8.0K | 505.0K | 13.66% | ↗ |
| 83 | 2011 | Hal Baker V.P., Commercial Operations | 250.0K | 178.0K | — | 69.0K | — | 8.0K | 505.0K | 13.66% | ↗ |
| 84 | 2011 | Jorge Artiles V.P., regulatory & Scientific Affairs, Chief Quality Officer | 253.0K | — | — | 69.0K | — | — | 322.0K | 21.43% | ↗ |
| 85 | 2011 | Moni Shavit Former V.P., Engineering | 149.0K | — | — | 69.0K | — | 59.0K | 277.0K | 24.91% | ↗ |
| 86 | 2011 | Ken Pappa V.P., Engineering & Manufacturing | 215.0K | — | — | 35.0K | — | — | 250.0K | 14.00% | ↗ |
| 87 | 2011 | Ken Pappa V.P., Manufacturing, Engineering and Quality | 215.0K | — | — | 35.0K | — | — | 250.0K | 14.00% | ↗ |
| 88 | 2010 | J. Melville Engle Chief Executive Officer | 350.0K | — | — | 91.0K | — | 21.0K | 462.0K | 19.70% | ↗ |
| 89 | 2010 | J. Melville Engle Former Chief Executive Officer | 350.0K | — | — | 91.0K | — | 21.0K | 462.0K | 19.70% | ↗ |
| 90 | 2010 | Jorge Artiles V.P., regulatory & Scientific Affairs, Chief Quality Officer | 170.0K | 89.0K | — | 95.0K | — | 94.0K | 448.0K | 21.21% | ↗ |
| 91 | 2010 | Jorge Artiles | 170.0K | 89.0K | — | 95.0K | — | 94.0K | 448.0K | 21.21% | ↗ |
| 92 | 2010 | Matthew T. Plavan CFO & EVP, Business Development | 298.0K | — | — | 110.0K | — | — | 408.0K | 26.96% | ↗ |
| 93 | 2010 | Matthew Plavan Chief Executive Officer & Chief Financial Officer | 298.0K | — | — | 110.0K | — | — | 408.0K | 26.96% | ↗ |
| 94 | 2010 | Hal Baker V.P., Commercial Operations | 221.0K | 65.0K | — | 97.0K | — | 7.0K | 390.0K | 24.87% | ↗ |
| 95 | 2010 | V.P., Chief Quality & Regulatory Affairs Officer Hal Baker | 221.0K | 65.0K | — | 97.0K | — | 7.0K | 390.0K | 24.87% | ↗ |
| 96 | 2010 | Moni Shavit Former V.P., Engineering | 215.0K | — | — | 54.0K | — | 3.0K | 272.0K | 19.85% | ↗ |
| 97 | 2010 | V.P., Commercial Operations Moni Shavit V.P., Engineering | 215.0K | — | — | 54.0K | — | 3.0K | 272.0K | 19.85% | ↗ |
| 98 | 2009 | William R. Osgood, Ph.D. Former, Chief Executive Officer | 150.0K | — | — | 20.0K | — | 437.0K | 607.0K | 3.29% | ↗ |
| 99 | 2009 | Matthew T. Plavan EVP, Chief Operating Officer, Chief Financial Officer | 275.0K | 30.0K | 8.0K | 140.0K | — | 7.0K | 460.0K | 32.17% | ↗ |
| 100 | 2009 | Matthew T. Plavan CFO & EVP, Business Development | 275.0K | 30.0K | 8.0K | 60.0K | — | 7.0K | 380.0K | 17.89% | ↗ |
| 101 | 2009 | Moni Shavit Former V.P., Engineering | 178.0K | 50.0K | — | 74.0K | — | 25.0K | 327.0K | 22.63% | ↗ |
| 102 | 2009 | V.P., Commercial Operations Moni Shavit V.P., Engineering | 178.0K | 50.0K | — | 74.0K | — | 25.0K | 327.0K | 22.63% | ↗ |
| 103 | 2009 | J. Melville Engle Chief Executive Officer | 73.0K | — | — | 237.0K | — | 4.0K | 314.0K | 75.48% | ↗ |
| 104 | 2009 | John Chapman, Ph.D. V.P., Scientific Affairs & Business Development | 215.0K | — | — | 70.0K | — | 7.0K | 292.0K | 23.97% | ↗ |
| 105 | 2009 | Les Schnoll | 210.0K | — | — | 15.0K | — | 64.0K | 289.0K | 5.19% | ↗ |
| 106 | 2009 | Sandra LaCava-Wilson Former, V.P., Sales | 151.0K | 32.0K | — | 2.0K | — | 99.0K | 284.0K | 0.70% | ↗ |
| 107 | 2009 | V.P., Quality & Regulatory Affairs Moni Shavit V.P., Research & Development | 178.0K | 50.0K | — | 17.0K | — | 25.0K | 270.0K | 6.30% | ↗ |
| 108 | 2008 | Philip H. Coelho Former Chief Technology Architect | 303.0K | — | 1.42M | — | — | 18.0K | 1.74M | 81.53% | ↗ |
| 109 | 2008 | William R. Osgood, Ph.D. Chief Executive Officer | 341.0K | — | — | 102.0K | — | 89.0K | 532.0K | 19.17% | ↗ |
| 110 | 2008 | William R. Osgood, Ph.D. Former, Chief Executive Officer | 341.0K | — | — | 102.0K | — | 89.0K | 532.0K | 19.17% | ↗ |
| 111 | 2008 | Matthew T. Plavan CFO & EVP, Business Development | 233.0K | — | — | 225.0K | — | 6.0K | 464.0K | 48.49% | ↗ |
| 112 | 2008 | Matthew T. Plavan EVP, Chief Operating Officer, Chief Financial Officer | 233.0K | — | 14.0K | 107.0K | — | 6.0K | 360.0K | 33.61% | ↗ |
| 113 | 2008 | Matthew T. Plavan Chief Financial Officer | 233.0K | — | 14.0K | 107.0K | — | 6.0K | 360.0K | 33.61% | ↗ |
| 114 | 2008 | John Chapman, Ph.D. V.P., Scientific Affairs & Business Development | 210.0K | — | — | 63.0K | — | 8.0K | 281.0K | 22.42% | ↗ |
| 115 | 2008 | John Chapman, Ph.D. V.P., Scientific Affairs | 210.0K | — | — | 63.0K | — | 8.0K | 281.0K | 22.42% | ↗ |
| 116 | 2008 | Sandra LaCava-Wilson Former, V.P., Sales | 146.0K | 67.0K | — | 16.0K | — | — | 229.0K | 6.99% | ↗ |
| 117 | 2008 | Sandra LaCava V.P., Sales | 146.0K | 67.0K | — | 16.0K | — | — | 229.0K | 6.99% | ↗ |
| 118 | 2008 | Dan Segal Former V.P., Emerging Stem Cell Therapy | 143.0K | — | — | 30.0K | — | 7.0K | 180.0K | 16.67% | ↗ |
| 119 | 2008 | John Groat V.P., Marketing | 145.0K | — | — | 12.0K | — | — | 157.0K | 7.64% | ↗ |
| 120 | 2007 | Philip H. Coelho Former Chief Technology Architect | 360.0K | — | 283.0K | 305.0K | — | 16.8K | 964.8K | 60.95% | ↗ |
| 121 | 2007 | Philip H. Coelho , Chairman and Chief Executive Officer | 360.0K | — | 283.0K | 305.0K | — | 16.8K | 964.8K | 60.95% | ↗ |
| 122 | 2007 | Kevin Simpson , Former President and GM, Surgical Wound Care | 194.6K | — | — | 38.9K | — | 52.7K | 286.2K | 13.59% | ↗ |
| 123 | 2007 | Matthew T. Plavan , Chief Financial Officer | 200.0K | — | 19.8K | 56.6K | — | 4.2K | 280.6K | 27.24% | ↗ |
| 124 | 2007 | Matthew T. Plavan EVP, Chief Operating Officer, Chief Financial Officer | 200.0K | — | 19.8K | 56.6K | — | 4.2K | 280.6K | 27.24% | ↗ |
| 125 | 2007 | Matthew T. Plavan Chief Financial Officer | 200.0K | — | 19.8K | 56.6K | — | 4.2K | 280.6K | 27.24% | ↗ |
| 126 | 2007 | John Chapman , V.P. of Scientific Affairs | 175.0K | — | — | 40.5K | — | 5.6K | 221.0K | 18.31% | ↗ |
| 127 | 2007 | John Chapman, Ph.D. V.P., Scientific Affairs & Business Development | 175.0K | — | — | 40.5K | — | 5.6K | 221.0K | 18.31% | ↗ |
| 128 | 2007 | John Chapman, Ph.D. V.P., Scientific Affairs | 175.0K | — | — | 40.5K | — | 5.6K | 221.0K | 18.31% | ↗ |
| 129 | 2007 | Dennis Marr , V.P. Research and Development | 175.0K | — | — | 37.7K | — | 4.0K | 216.8K | 17.41% | ↗ |
| 130 | 2007 | William R. Osgood, Ph.D. Chief Executive Officer | 136.0K | — | — | 43.5K | — | 19.2K | 198.7K | 21.90% | ↗ |
| 131 | 2007 | William R. Osgood, Ph.D. Former, Chief Executive Officer | 136.0K | — | — | 43.5K | — | 19.2K | 198.7K | 21.90% | ↗ |
| 132 | 2007 | William Osgood , President and Chief Operating Officer | 136.0K | — | — | 43.5K | — | 19.2K | 198.7K | 21.90% | ↗ |
| 133 | 2003 | Kevin Simpson, President and Chief Operating Officer Renee M. Ruecker, Chief Financial Officer | 109.0K | 35.0K | — | 300.0K | — | 17.0K | 461.0K | 65.08% | ↗ |
| 134 | 2003 | Philip H. Coelho Chairman and Chief Executive Officer Kevin Simpson, President and Chief Operating Officer | 224.0K | — | — | — | — | 12.0K | 236.0K | 0.00% | ↗ |
| 135 | 2003 | Renee M. Ruecker, Chief Financial Officer Dan Segal, V.P. Sales/Marketing | 133.0K | — | — | 100.0K | — | 1.0K | 234.0K | 42.74% | ↗ |
| 136 | 2003 | Sam Acosta, V.P. Manufacturing Operations | 149.0K | — | — | — | — | 3.0K | 152.0K | 0.00% | ↗ |
| 137 | 2003 | Dan Segal, V.P. Sales/Marketing Sam Acosta, V.P. Manufacturing Operations | 145.0K | — | — | — | — | — | 145.0K | 0.00% | ↗ |
| 138 | 2002 | Philip H. Coelho Chairman and Chief Executive Officer | 188.6K | 22.0K | — | 1.00M | — | 10.0K | 1.22M | 81.93% | ↗ |
| 139 | 2002 | Dan Segal, V.P. Sales/Marketing | 121.8K | — | — | 100.0K | — | 4.0K | 225.8K | 44.29% | ↗ |
| 140 | 2002 | Sam Acosta, V.P. Manufacturing Operations | 141.8K | — | — | — | — | 3.0K | 144.8K | 0.00% | ↗ |
| 141 | 2002 | Renee M. Ruecker, Chief Financial Officer | 115.5K | — | — | — | — | — | 115.5K | 0.00% | ↗ |
| 142 | 2001 | Philip H. Coelho Chairman and Chief Executive Officer | 181.0K | — | — | 350.0K | — | 30.0K | 561.0K | 62.39% | ↗ |
| 143 | 2001 | Dan Segal, V.P. Sales/Marketing Sam Acosta, V.P. Manufacturing Operations | 136.0K | — | — | 95.0K | — | 9.0K | 240.0K | 39.59% | ↗ |
| 144 | 2001 | Renee M. Ruecker, Chief Financial Officer Dan Segal, V.P. Sales/Marketing | 113.0K | — | — | 50.0K | — | 4.0K | 167.0K | 29.94% | ↗ |
| 145 | 2001 | Kevin Simpson, President and Chief Operating Officer Renee M. Ruecker, Chief Financial Officer | 109.0K | — | — | — | — | 1.0K | 110.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Xiaochun Xu | Chairman of the Board & Chief Executive Officer | 520.0K | — |
| Haihong Zhu | Chief Operating Officer | 460.0K | female |
ESG Rating
ESG Score History MEDICAL - DEVICES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for THMO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
